Tocotrienols supplementation improves arterial compliance in healthy men, study shows
Highlights
- EVNol SupraBio™ mixed tocotrienols significantly improves arterial compliance in healthy men.
- Arterial compliance measured by carotid femoral pulse wave velocity and augmentation index
- Effective dosage is 100 to 200 mg/day for 2 months
Summary
This randomized, placebo controlled, double-blind study was designed to determine the effects of various doses of mixed tocotrienols on arterial compliance and vitamin E blood levels.
For this study, researchers randomly assigned 36 healthy men, mean age 24 years, to one of four treatment groups: 50, 100 or 200 mg/day of EVNol Suprabio™ (formerly Tocomin SupraBio™)* mixed tocotrienols or placebo for 2 months. Researchers assessed the blood levels of vitamin E, total cholesterol, and LDL cholesterol as well as arterial compliance (as measured by carotid femoral pulse wave velocity and augmentation index) before and after 2 months of treatment.
Compared to the placebo group, all tocotrienol-treated groups had significantly higher blood levels of tocotrienols after 2 months of treatment. The groups taking the higher dosages of tocotrienols (100 and 200 mg daily) had significant (P<.05) improvements in arterial compliance after treatment. No effect on blood lipids with tocotrienols was reported. Overall good tolerability with treatment was reported with no adverse effects requiring study withdrawal.
These findings indicate daily supplementation with EVNol SupraBio™ mixed tocotrienols (100-200 mg/day for 4 weeks) improves arterial compliance in healthy men.
*The study treatment (TOCOVID SupraBio™ softgels) is identical to EVNol SupraBio™ softgels. EVNol SupraBio is a trademark of ExcelVite Inc and protected by US Patent No – 6,596,306 and 7,211,274.
